Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma | Zendy

Olivier Chinot | Zendy; Wolfgang Wick | Zendy; Warren Mason | Zendy; Roger Henriksson | Zendy; Frank Saran | Zendy; Ryo Nishikawa | Zendy; Alain Carpentier | Zendy; Khê HoangXuan | Zendy; Petr Kavan | Zendy; Dana Cernea | Zendy; Alba A. Brandes | Zendy; Magalie Hilton | Zendy; Lauren E. Abrey | Zendy; Timothy F. Cloughesy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

Author(s) -

Olivier Chinot,

Wolfgang Wick,

Warren Mason,

Roger Henriksson,

Frank Saran,

Ryo Nishikawa,

Alain Carpentier,

Khê HoangXuan,

Petr Kavan,

Dana Cernea,

Alba A. Brandes,

Magalie Hilton,

Lauren E. Abrey,

Timothy F. Cloughesy

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1308345

Subject(s) - medicine , temozolomide , bevacizumab , hazard ratio , placebo , radiation therapy , surgery , progression free survival , confidence interval , chemotherapy , pathology , alternative medicine

Standard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to radiotherapy-temozolomide for the treatment of newly diagnosed glioblastoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research